AstraZeneca's Tagrisso has received European Commission approval for treating advanced non-small cell lung cancer, showing a median progression-free survival of over three years in late-stage trials.
The FDA revoked the emergency use authorization for AstraZeneca's Evusheld due to its expired shelf life and lack of patient administration approval for over a year.
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.